Journal
FRONTIERS IN AGING NEUROSCIENCE
Volume 14, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fnagi.2022.899158
Keywords
Alzheimer's disease; amyloid deposition; cognition; depressive symptoms; anxiety; glucose metabolism; subjective cognitive decline; gray matter
Categories
Funding
- Agence Nationale de la Recherche (LONGVIE, 2007) Association France Alzheimer et maladies apparentees AAP 2013
- Fondation Plan Alzheimer (Alzheimer Plan 2008-2012)
- Institut National de la Sante et de la Recherche Medicale (INSERM)
- European Union's Horizon2020 Research and Innovation Program [667696]
- Programme Hospitalier de Recherche Clinique [PHRCN 2011-A01493-38, PHRCN 2012 12-006-0347]
- Region Basse-Normandie
- French Ministere de l'Enseignement Superieur et de la Recherche
- French ministerial scholarship and University grant for traveling and attending a scientific meeting in Berlin
- Inserm
- European Union Horizon 2020
- Alzheimer's Society
- European Union Horizon 2020 and Medical Research Council
- European Union's Horizon 2020 research and innovation programme
- EU's Horizon 2020 research and innovation programme [667696]
- Fondation d'entreprise MMA des Entrepreneurs du Futur
- Fondation Alzheimer
- Programme Hospitalier de Recherche Clinique
- Region Normandie
- Association France Alzheimer et maladies apparentees
- Fondation Vaincre Alzheimer
- H2020 Societal Challenges Programme [667696] Funding Source: H2020 Societal Challenges Programme
Ask authors/readers for more resources
This study found that depressive symptoms are more severe in patients with subjective cognitive decline and cognitively impaired patients on the Alzheimer's continuum compared to healthy controls. Depressive symptoms were associated with higher amyloid load in subjective cognitive decline patients, while they were related to higher cognition and glucose metabolism in cognitively impaired patients on the Alzheimer's continuum.
BackgroundDepressive and anxiety symptoms are frequent in Alzheimer's disease and associated with increased risk of developing Alzheimer's disease in older adults. We sought to examine their relationships to Alzheimer's disease biomarkers across the preclinical and clinical stages of the disease. MethodFifty-six healthy controls, 35 patients with subjective cognitive decline and 56 amyloid-positive cognitively impaired patients on the Alzheimer's continuum completed depression and anxiety questionnaires, neuropsychological tests and neuroimaging assessments. We performed multiple regressions in each group separately to assess within group associations of depressive and anxiety symptoms with either cognition (global cognition and episodic memory) or neuroimaging data (gray matter volume, glucose metabolism and amyloid load). ResultsDepressive symptoms, but not anxiety, were higher in patients with subjective cognitive decline and cognitively impaired patients on the Alzheimer's continuum compared to healthy controls. Greater depressive symptoms were associated with higher amyloid load in subjective cognitive decline patients, while they were related to higher cognition and glucose metabolism, and to better awareness of cognitive difficulties, in cognitively impaired patients on the Alzheimer's continuum. In contrast, anxiety symptoms were not associated with brain integrity in any group. ConclusionThese data show that more depressive symptoms are associated with greater Alzheimer's disease biomarkers in subjective cognitive decline patients, while they reflect better cognitive deficit awareness in cognitively impaired patients on the Alzheimer's continuum. Our findings highlight the relevance of assessing and treating depressive symptoms in the preclinical stages of Alzheimer's disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available